Cart
sales@molnova.com
Cdc7 inhibitor 7c
CAS No. 1330781-04-8
Cdc7 inhibitor 7c( Cdc7-IN-7c | Cdc7 IN 7c | Cdc7IN7c | Cdc7 inhibitor 7c )
Catalog No. M11315 CAS No. 1330781-04-8
A highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 745 | Get Quote |
|
| 10MG | 1017 | Get Quote |
|
| 25MG | 1431 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | 4410 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCdc7 inhibitor 7c
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively.
-
DescriptionA highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively; exhibits significant time-dependent Cdc7 inhibition with slow dissociation kinetics, cellular pharmacodynamic (PD) effects, and COLO205 growth inhibition.
-
In Vitro——
-
In Vivo——
-
SynonymsCdc7-IN-7c | Cdc7 IN 7c | Cdc7IN7c | Cdc7 inhibitor 7c
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1330781-04-8
-
Formula Weight315.395
-
Molecular FormulaC15H17N5OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2=C(C=C(C3=CNN=C3C)S2)N=C(CN4CCCC4)N1
-
Chemical Name6-(3-methyl-1H-pyrazol-4-yl)-2-(pyrrolidin-1-ylmethyl)thieno[3,2-d]pyrimidin-4(3H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kurasawa O, et al. Bioorg Med Chem. 2017 Jul 15;25(14):3658-3670.
molnova catalog
related products
-
Amsilarotene
Amsilarotene inhibits the phosphorylation of retinoblastoma gene product (RB) and increases the presence of 2 cyclin-dependent kinases (CDK) inhibitors resulting in cell cycle arrest.
-
Ro-3306
RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.
-
Ibulocydine
Ibulocydine is the prodrug of CDK inhibitor BMK-Y101, inhibits CDK7 and CDK9 with IC50 of 530 nM and 85 nM in kinase assays, respectively.
